Targeting Refractory Lupus Nephritis in Children

Systemic lupus erythematosus (SLE), particularly its most severe form, lupus nephritis, poses notable challenges in pediatric care. Recent research from the Giannina Gaslini Institute, published in Frontiers in Immunology, offers a beacon of hope with novel therapeutic approaches.

The study details the successful combined use of Rituximab (anti-CD20) and Daratumumab (anti-CD38) monoclonal antibodies in two young patients whose lupus nephritis had proven resistant to conventional treatments.This innovative strategy, coordinated by the Nephrology and Rheumatology departments at Gaslini, marks a potential turning point in managing this challenging condition.

This approach has led to a stable remission of the disease, while reducing toxicity and prolonged exposure to immunosuppressants. The results obtained suggest a possible paradigm change in the management of the refractory pediatric lupus, opening the way to new more targeted and effective therapeutic strategies.
Andrea angeletti, Nephrology of Gaslini

Andrea Angeletti, a lead author of the study from the Nephrology department at Gaslini, emphasized the potential for a paradigm change in treating refractory pediatric lupus. The combined antibody approach aims to minimize the adverse effects associated with long-term immunosuppression, a common concern in lupus management.

The combined use of these monoclonal antibodies represents an important innovation in the treatment of pediatric nephritical lupus resistant to conventional therapies…The results obtained in our patients indicate a concrete possibility of improving the prognosis of this serious disease, minimizing the side effects of long-term immunosuppressive therapies. The goal is to offer children with Les a more effective and less invasive therapeutic option.
Enrico Verrina, director of the Gaslini Nephrology

Enrico Verrina, director of Gaslini Nephrology, highlighted the significance of this advancement, stating that it offers a concrete possibility of improving the prognosis for children with lupus nephritis while reducing the burden of side effects from traditional treatments.

CAR-T Cell Therapy: A Cutting-Edge Frontier

Beyond the antibody combination, Gaslini is also pioneering the use of CAR-T cell therapy for pediatric lupus. This advanced approach involves genetically modifying a patientS T lymphocytes to target and eliminate the autoimmune B cells responsible for the disease.This project is a collaborative effort involving nephrology, bone marrow transplantation, pharmacy, transfusion center, and rheumatology teams.

If successful, CAR-T cell immunotherapy could revolutionize the treatment landscape, potentially leading to long-term remission and reducing the reliance on chronic immunosuppression. This,in turn,could significantly improve the quality of life for young patients battling refractory pediatric lupus.

Understanding pediatric Lupus Erythematosus (SLE)

Pediatric systemic lupus erythematosus (SLE) is a rare autoimmune disorder affecting children and adolescents. In SLE, the immune system mistakenly attacks healthy tissues and organs, leading to widespread inflammation. This inflammation can impact various parts of the body, including the skin, joints, heart, lungs, and nervous system [[1]], [[3]].

Lupus nephritis, a severe manifestation of SLE, affects the kidneys, potentially leading to kidney failure. According to the Lupus Foundation of America, lupus nephritis occurs in up to 60% of children with SLE. Managing lupus nephritis, especially when it resists standard treatments, necessitates the development of innovative and targeted therapeutic strategies [[2]].